Mahkam Zanganeh - Jan 2, 2025 Form 4 Insider Report for Summit Therapeutics Inc. (SMMT)

Role
Co-Chief Executive Officer, Director, 10%+ Owner
Signature
/s/ Mahkam Zanganeh
Stock symbol
SMMT
Transactions as of
Jan 2, 2025
Transactions value $
$98,446
Form type
4
Date filed
1/6/2025, 07:39 PM
Previous filing
Oct 3, 2024
Next filing
Feb 11, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SMMT Common Stock 31K Jan 2, 2025 Direct
holding SMMT Common Stock 10.2M Jan 2, 2025 By the Shaun Zanganeh Irrevocable Trust, with the Reporting Person as Trustee F1
holding SMMT Common Stock 25.5M Jan 2, 2025 By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee F1
holding SMMT Common Stock 50K Jan 2, 2025 Immediate family member F1
holding SMMT Common Stock 552M Jan 2, 2025 By Spouse F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SMMT Stock Option (right to buy) Award $98.4K +10.7K $9.18 10.7K Jan 2, 2025 Common Stock 10.7K $18.35 By Spouse F1, F3
holding SMMT Warrant (right to buy) 3.99M Jan 2, 2025 Common Stock 3.99M $1.58 By Spouse F1, F2
holding SMMT Stock Option (right to buy) 74.5K Jan 2, 2025 Common Stock 74.5K $2.64 By Spouse F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
F2 The Reporting Person acquired beneficial ownership of these securities upon her marriage to the beneficial owner of the securities on December 18, 2024.
F3 The option was granted on January 2, 2025 to the Reporting Person's spouse. The shares underlying the option shall vest in four quarterly installments, subject to continued service on each vesting date.
F4 The option was granted on January 2, 2024 to the Reporting Person's spouse. The shares underlying the option are fully vested.